Ensysce Biosciences, Inc. Logo

Ensysce Biosciences, Inc.

Developing safer opioids with abuse-deterrent and overdose protection technology for severe pain.

ENSC | US

Overview

Corporate Details

ISIN(s):
US2936021086 (+2 more)
LEI:
Country:
United States of America
Address:
7946 IVANHOE AVENUE, 92037 LA JOLLA
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Ensysce Biosciences, Inc. is a clinical-stage biotechnology company dedicated to developing safer prescription drugs for severe pain to address the opioid epidemic. The company utilizes its proprietary technology platforms, Trypsin-Activated Abuse Protection (TAAP™) and Multi-Pill Abuse Resistance (MPAR®), to create novel opioids with built-in abuse deterrence and overdose protection. The TAAP™ platform creates prodrugs that are activated only in the gastrointestinal tract, minimizing abuse via non-oral routes. The MPAR® system is designed to prevent overdose by limiting drug activation when excessive doses are consumed. The company's lead product candidate, PF614, has received 'Fast Track' and 'Breakthrough Therapy' designations from the FDA.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Ensysce Biosciences, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Ensysce Biosciences, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Ensysce Biosciences, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Kancera Logo
Develops small molecule drugs targeting the fractalkine axis for cancer and inflammatory diseases.
Sweden
KAN
KANGSTEM BIOTECH CO., LTD. Logo
Develops stem cell therapies for rare diseases; offers culture media, cell platforms, and CDMO services.
South Korea
217730
Karo Pharma AB Logo
Develops and sells everyday healthcare products, focusing on OTC and skin health in Europe.
Sweden
KARO
Karyopharm Therapeutics Inc. Logo
Develops novel oral cancer therapies by inhibiting nuclear export for hard-to-treat tumors.
United States of America
KPTI
KAZIA THERAPEUTICS LTD Logo
Oncology-focused drug development firm advancing anti-cancer candidates for brain cancers in trials.
United States of America
KZIA
KBIO COMPANY Inc. Logo
Using a plant-based platform to rapidly develop biologics for public health.
South Korea
038530
Keeps Biopharma Inc. Logo
Develops cancer therapies and obesity drugs; manufactures industrial and cleanroom products.
South Korea
256940
Kidswell Bio Corporation Logo
Biopharma R&D of biosimilars, biologics, and cell therapies, with a pediatric focus.
Japan
4584
Kinarus Therapeutics Holding AG Logo
A specialty pharma firm developing and selling medicines for rare and specialty diseases.
Switzerland
KNRS
Kiniksa Pharmaceuticals International, plc Logo
Develops and commercializes immune-modulating therapies for debilitating diseases with unmet needs.
United States of America
KNSA

Talk to a Data Expert

Have a question? We'll get back to you promptly.